Epithelial Ovarian Cancer: Clinical Relevance of Deregulation of Long Noncoding RNAs
Posted: Wednesday, May 1, 2019
According to a molecular research study conducted by Yong Zeng, PhD, of the Engineering Technology Research Center, Changsha, China, and colleagues, HOXD-AS1 looks to be at the center of a clinically relevant molecular pathway in epithelial ovarian cancer. The study, which was published in the Journal of Experimental & Clinical Cancer Research, explored the deregulation of long noncoding RNAs, which are known to be implicated in various oncogenic processes.
“HOXD-AS1/miR-186-5p/PIK3R3 is a novel pathway to promote cell migration, invasion, and epithelial-mesenchymal transition in epithelial ovarian cancer,” the scientists concluded.
Using expression microarrays, Dr. Zeng and colleagues profiled long noncoding RNAs, mRNAs, and miRNAs. They used reverse transcription quantitative polymerase chain reaction in epithelial ovarian cancer cells and tissues. To regulate endogenous target expression in epithelial ovarian cancer cell lines in vitro, the scientists used siRNAs aimed at either HOXD-AS1 or PIK3R3 and miR-186-5p inhibitors. To determine the biologic and molecular characteristics of HOXD-AS1 in the cancer cells, they used an assortment of different assays.
Significant overexpression of HOXD-AS1 was found in the tumors, and the high expression seemed to be correlated with poorer progression-free and overall survival. “We observed a significantly inverse correlation between HOXD-AS1/miR-186-5p and between miR-186-5p/PIK3R3 in an independent cohort of 200 epithelial ovarian cancer tissues,” the scientists commented. “These data suggest that HOXD-AS1 may function as a master regulator of metastasis through its interaction with a number of miRNAs and their respective target genes,” they proposed.
Disclosure: The study authors reported no conflicts of interest.